The INHBE Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the human 143B osteosarcoma line, designed with targeted disruption of INHBE. This loss-of-function model abolishes inhibin beta E expression, enabling dissection of its function in TGF-beta superfamily signaling and metabolic pathways. The polyclonal nature integrates diverse gene edits, mitigating clonal bias and ensuring reproducible functional outcomes across assays.
143B is a human osteosarcoma cell line exhibiting epithelial morphology, originally derived from a 13-year-old female. It serves as a canonical model for osteosarcoma biology due to its robust proliferation and genetic manipulability. Although not of hepatic origin, 143B cells express essential TGF-beta receptors and SMAD proteins, providing a tractable system for studying inhibin beta E-activated intracellular cascades in a controlled, proliferative background.
The INHBE gene encodes inhibin beta E, a TGF-beta superfamily ligand primarily characterized in hepatic glucose homeostasis and insulin sensitivity. Its expression is induced by glucagon and fasting through the transcription factors FOXO1 and CREB, and suppressed by insulin. The secreted inhibin beta E homodimers or heterodimers with INHBA bind to TGFBR1/TGFBR2 receptor complexes, activating phosphorylation of SMAD2 and SMAD3. These receptor-regulated SMADs form complexes with SMAD4 and translocate to the nucleus, where they modulate genes controlling gluconeogenesis and insulin signaling, such as key rate-limiting metabolic enzymes. Thus, INHBE functions as a metabolic sensor linking extracellular hormonal cues to adaptive gene expression, with implications for type 2 diabetes and obesity.
Removing INHBE from the 143B genome creates a clean cellular backdrop free from endogenous inhibin beta E activity, ideal for reconstitution experiments and pathway dissection. The polyclonal knockout pool reflects multiple allelic disruptions, reducing the likelihood of phenotype dominance by a single clone and enhancing data reliability in comparative studies. This model permits precise measurement of ligand-induced SMAD2/3 activation, assessment of receptor specificity, and investigation of signaling crosstalk without endogenous interference.
These knockout cells support research into hepatic insulin resistance mechanisms, either by transiently expressing liver-enriched factors or via conditioned media experiments. Common applications include western blot detection of phospho-SMAD2/3, RT-qPCR for gluconeogenic gene panels, glucose production assays, and insulin sensitivity tests. RNA-sequencing comparisons between knockout and parental 143B lines can delineate INHBE-dependent transcriptomes under metabolic stimuli. The polyclonal knockout also provides a negative control for antibody validation and a host for ectopic INHBE mutant expression to map functional domains. For additional details or to place an order, contact Ascent Research.
